Truth About Benefits of HRT For Women, and COVID Lies Uncovered, w/ FDA Commissioner Marty Makary
What this video covers
In this bonus episode of The Megyn Kelly Show, host Megyn Kelly interviews Dr. Marty Makary — then serving as FDA Commissioner — on a slate of topics spanning women’s health, pregnancy medication risks, and pandemic-era government science. The conversation centers on hormone replacement therapy (HRT), with Makary arguing that a landmark 2002 study, the Women’s Health Initiative, wrongly frightened a generation of women away from treatment that he says can reduce heart attacks and dementia and improve sleep.
Makary also raises concerns about antidepressant and SSRI use during pregnancy, citing data he says shows potential dangers including birth defects. The interview touches on what he describes as alarming developments in Chinese gene therapy — he repeats his claim that the FDA had approved sending American cancer patients’ cells to China for gene editing before they were shipped back and infused — and on what he says he has uncovered inside the FDA about the COVID response.
On HRT, Makary personalizes the story through his mother: he says she broke bones twice in falls, went through a borderline surgery decision, and was one of the “50 plus million women” never offered therapy. He notes an 80-year-old woman has a one-in-three chance of a hip fracture, and that a quarter of women die within a year of one. He describes confronting the Women’s Health Initiative lead author, Jacques Rossouw, about the breast-cancer finding: “He answered, quote, ‘it touched on significance but wasn’t quite significant. It was nominally significant. It was not significant after being adjusted for multiple looks at the data.’” And he cites the 1950s Mayo observation that young women whose ovaries were removed developed early heart disease — including, he says, a fatal heart attack at age 28 — as evidence of estrogen’s cardioprotective effect. Throughout, Kelly frames the conversation as a corrective to what both describe as years of flawed or incomplete official messaging.
The episode aired in July 2025, months before Makary’s FDA moved to remove long-standing black-box warnings from HRT labels — a policy shift covered in his later November 2025 media appearances. Makary’s claims about HRT benefits, pregnancy medication risks, and COVID-era findings are presented as his arguments; the site does not endorse medical claims.
Key points
- Makary argues the 2002 Women’s Health Initiative study was flawed and scared women away from hormone replacement therapy, leaving millions without treatment he says could have reduced heart attacks and dementia.
- He discusses new data he says shows potential dangers of taking antidepressants and SSRIs during pregnancy, including a possible link to birth defects — presented as his reading of emerging research.
- Makary raises what he calls “shocking information” about Chinese gene therapy work, though the description offers no detail on the specific claims.
- He discusses what he says he has uncovered at the FDA about the COVID response, positioning himself as a reformer revealing suppressed findings.
- The episode previews the HRT policy shift Makary would pursue at the FDA: revisiting and ultimately removing the black-box warnings added after the 2002 study.
- Kelly’s framing throughout treats Makary as an insider whistleblower on establishment medicine — a posture consistent with his pre-FDA reputation as a critic of pandemic management.